enGenes Biotech Launches Its New Website

news-releasesenGenes Biotech GmbH

March 20th 2024

Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) now has a fresh and more comprehensive web presence with a redesigned and re-engineered website at www.engenes.cc.

The new website features a clear, uncluttered and logical design with its Home page delivering direct links to the key elements of the enGenes offer in Recombinant Protein and Plasmid DNA production, as well as its various strengths and capabilities.

New content

The top menu structure with pull-down functionality provides pathways to enGenes Services, Technologies, and Company overview including key team member profiles, latest news/events and Contact information.

Proprietary and patented enGenes high-yield technologies such as -e^xpress™, -e^xcite™, -e^xpand™, -e^xpand™, -e^xcess™, and -e^xtra™ are all now specifically presented in detail and context, with links to supporting scientific publications.

Segmented and relevant

CEO of enGenes, Dr. Juergen Mairhofer, commented: “We wanted to provide a clearer overview of all our technologies and service offerings as well as introducing our team.”

“This new website is a clear step forward from its predecessor, which had been in place for quite some time and was becoming increasingly hard to navigate. We can now be confident we are presenting all the relevant information on our recombinant protein and pDNA services and technologies in a segmented way that can inform and attract existing and potential customers,” Dr. Mairhofer concluded.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes -e^Xpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes -e^Xpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.